The Efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 Probiotic Treatment in Infants with Rotavirus Infection
Department of Hotel Culinary Arts, Yeonsung University, Anyang 430-749, Korea
Research Center, BIFIDO Co. Ltd., Hongcheon 250-804, Korea
Fermentation Science Program, School of Agribusiness and Agriscience, College of Basic and Applied Sciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA
Department of Food and Nutrition, Research Institute of Human Ecology, Seoul National University, Seoul 151-742, Korea
Author to whom correspondence should be addressed.
Nutrients 2017, 9(8), 887; https://doi.org/10.3390/nu9080887
Received: 5 July 2017 / Revised: 26 July 2017 / Accepted: 4 August 2017 / Published: 16 August 2017
(This article belongs to the Special Issue Prebiotics and Probiotics)
A total of 57 infants hospitalized with rotavirus disease were included in this study. The children were randomly divided into the study’s two treatment groups: three days of the oral administration of (i) a probiotics formula containing both Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 (N = 28); or (ii) a placebo (probiotic-free skim milk, N = 29) and the standard therapy for diarrhea. There were no differences in age, sex, or blood characteristics between the two groups. When the 57 cases completed the protocol, the duration of the patients’ diarrhea was significantly shorter in the probiotics group (4.38 ± 1.29, N = 28) than the placebo group (5.61 ± 1.23, N = 29), with a p-value of 0.001. Symptoms such as duration of fever (p = 0.119), frequency of diarrhea (p = 0.119), and frequency of vomiting (p = 0.331) tended to be ameliorated by the probiotic treatment; however, differences were not statistically significant between the two groups. There were no serious, adverse events and no differences in the frequency of adverse events in both groups.